The Difference Between Semax and Selank

Which one does what? If you have seen these two peptides named in the same breath and cannot tell them apart, the difference between Semax and Selank comes down to parentage. Semax is built from a fragment of a pituitary hormone, and its research sits in cognition and stroke neuroprotection. Selank is built from a fragment of an antibody, and its research sits in anxiety, stress and immune signaling. Structure, route, evidence and regulatory status all follow from that one split.

Same length, different family trees

Structurally these are cousins, not opposites. Semax is Met-Glu-His-Phe-Pro-Gly-Pro; Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro. Seven residues each, and the last three are identical. What differs is the first four: Semax's come from adrenocorticotropic hormone, Selank's from tuftsin, a naturally occurring tetrapeptide found in the heavy chain of human immunoglobulin G.

Both were assembled at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank in cooperation with the V.V. Zakusov Research Institute of Pharmacology. The shared Pro-Gly-Pro tail is not decoration: short natural peptide fragments are broken down quickly by enzymes, and that extension resists degradation while leaving the neurotropic part intact. For Semax, review data put the duration of effect at roughly 20 to 24 hours after an intranasal dose (PMID 9173745). Fragment studies sharpen the point: Gly-Pro alone reproduced much of Selank's gene-expression profile, while bare Pro-Gly-Pro's influence in an ischemia model was mainly unspecific — evidence that the shared tail contributes real activity of its own.

One correction worth making: Semax is often written as "the ACTH(4-10) sequence with Pro-Gly-Pro added," which would be a ten-residue molecule. The primary literature is explicit that it is an ACTH(4-7) fragment plus a C-terminal PGP tripeptide — an analog of ACTH(4-10), not an extension of it (PMID 19633950).

The difference between Semax and Selank at a glance

Same length, different parent molecules, different best-evidenced mechanisms, and very different amounts of human data. Semax's research centre of gravity is cognition and ischemic injury; Selank's is anxiety, stress and immune signaling. Neither has a large modern randomized trial behind it.

What each one does in the body

Semax works through neurotrophins; Selank works through the GABA system. That is the cleanest mechanistic contrast available, with one caveat: both touch more than one system, and BDNF is not exclusive to Semax.

A single intranasal dose of Semax at 50 µg/kg in rats produced a 1.4-fold increase in BDNF protein, a 1.6-fold increase in trkB tyrosine phosphorylation, a 3-fold increase in exon III BDNF mRNA and a 2-fold increase in trkB mRNA in the hippocampus (PMID 16996037). In rat basal-forebrain glial cultures, Semax raised BDNF mRNA about 8-fold and NGF mRNA about 5-fold, peaking within 30 minutes (PMID 11457573). A companion study found BDNF rising at 3 hours in the rat basal forebrain but not the cerebellum after intranasal doses of 50 and 250 µg/kg, and identified specific, calcium-dependent Semax binding sites there (KD 2.4 ± 1.0 nM) (PMID 16635254). In rats with permanent middle cerebral artery occlusion, Semax enhanced transcription of Bdnf, TrkC and TrkA at 3 hours and of Nt-3 and Ngf at 24 hours, selectively in the ischemic cortex (PMID 19633950). That pathway gets a fuller treatment in how Semax works.

Selank was characterized as a positive allosteric modulator of GABA receptors by radioligand binding analysis with tritiated GABA on brain-cell membranes — it changes how the receptor responds rather than occupying the site a benzodiazepine would (PMID 30255741). In rat frontal cortex, a 300 µg/kg dose altered expression in 45 of 84 neurotransmission-related genes at 1 hour, with 22 still altered at 3 hours (PMID 26924987); in IMR-32 human neuroblastoma cells, by contrast, Selank alone changed no GABAergic gene expression — shifts appeared only when it was combined with GABA or olanzapine (PMID 28293190). Selank also appears to slow the breakdown of enkephalins, the body's own short opioid peptides: in the 62-patient trial, the shortened serum half-life of leu-enkephalin rose during treatment (PMID 18454096). And intranasal Selank regulates BDNF in the rat hippocampus in vivo (PMID 18841804) — "Semax is the BDNF one" is a simplification, not a rule.

What the human evidence covers, and what it does not

Two human studies carry this comparison, and both are small. The first is a 2008 Russian-language trial of 62 patients with generalized anxiety disorder or neurasthenia, split between Selank (n=30) and the benzodiazepine medazepam (n=32) and assessed on the Hamilton, Zung and CGI scales; the published conclusion was that the anxiolytic effects of the two drugs were similar, with Selank also showing antiasthenic and psychostimulant effects (PMID 18454096). That is the whole of the controlled clinical evidence on either compound's target symptoms.

The second is the only true head-to-head: 52 healthy participants underwent resting-state fMRI three times — before, 5 minutes after, and 20 minutes after receiving Semax, Selank or placebo by injection. The reported finding was a difference in functional connectivity between the right amygdala and a right-hemisphere region spanning the fusiform, inferior and middle temporal, and parahippocampal gyri, described by the authors as both general and specific effects on that connection (PMID 32342318). Precision matters here, because the popular summary of this study — Selank acting on the limbic system while Semax acts on the prefrontal cortex — is not what the paper reports. Both compounds moved the same amygdala-centred circuit, in one imaging session, in healthy volunteers.

Route matters too. Human research on both compounds is overwhelmingly intranasal and Russian: 11 of the 12 published human Semax studies used intranasal dosing, and Semax's Russian registration covers intranasal drops only. The head-to-head imaging study is the exception, reporting injection. A licensed provider may still prescribe — that decision is between you and your doctor.

Safety data is thin to match. The most-reported adverse effects in Semax review literature are nasal-cavity discoloration in roughly 10% of patients and raised blood glucose in about 7.4% of patients with diabetes; effects beyond about a month of continuous use are not established, and neither compound has safety data in pregnancy, in breastfeeding, or in people under 18.

Where Selank's evidence goes that Semax's does not

Selank has two research lanes Semax does not: stress and withdrawal behaviour, and immune signaling. Both trace back to its tuftsin parentage, and both are rodent work using intraperitoneal injection rather than the intranasal route of the human studies.

In an unpredictable chronic mild stress model assessed on the elevated plus maze, Selank given individually was most effective at reducing the elevated anxiety indicators induced by the course of test substances, and a diazepam-plus-Selank combination was most effective under chronic stress (PMID 28280289). The same study carries a caveat: a course of the test substances worsened anxiety indicators even in unstressed animals, though less so after Selank.

In naloxone-precipitated morphine withdrawal in rats, a single 0.3 mg/kg intraperitoneal dose of Selank reduced the total withdrawal index by 39.6% and raised the tactile sensitivity threshold 9-fold; diazepam at 2 mg/kg reduced the index by 49.3% with a 13-fold increase, making Selank slightly inferior to diazepam in the authors' words (PMID 36322304). In rats given 10% ethanol as their sole fluid for 30 weeks, Selank at 0.3 mg/kg/day intraperitoneally for 7 days prevented an ethanol-induced increase in BDNF in the hippocampus and frontal cortex — prevention of a rise, not restoration of a fall (PMID 31625062).

The immune lane is Selank's alone. In socially stressed rats, Selank at 100 µg/kg/day intraperitoneally across a 20-day stress period decreased IL-1β and IL-6, restored IL-4 and suppressed TGF-β1 (PMID 32621722); in mouse spleen, a single 100 µg/kg dose cut complement C3 mRNA 3-fold at 30 minutes (PMID 24291245). Semax has no comparable cytokine literature.

If what draws you to Selank is night-time restlessness rather than daytime tension, that is a different question — DSIP is the compound most often raised in sleep contexts.

Can Semax and Selank be taken together?

There is no published evidence on the combination. Not a trial, not a case series — the two have never been studied administered together, and the one imaging study that included both ran them as separate arms. Any claim about what the pair does jointly is inference, not data.

That matters because the two are sometimes prescribed as a single compounded preparation. The accurate framing: two separately studied peptides with distinct mechanisms, which a provider may choose to prescribe together on mechanistic reasoning rather than combination trials. The only pairing formally studied in this literature is Selank with diazepam, in rats.

Approved in Russia, not approved by the FDA

Both compounds are registered pharmaceuticals in Russia, and in the United States they are not FDA-approved. Semax has been a registered prescription drug there since the 1990s, sold as intranasal drops in 0.1% and 1% strengths — the lower strength registered for cognitive and asthenic indications, the 1% solution for acute ischemic stroke and optic-nerve atrophy, where it has been used in Russian clinical practice (Dmitrieva 2008); Selank has been approved in Russia for generalized anxiety disorder since 2009.

A foreign approval is not a shortcut to a U.S. one. The FDA has stated in writing that an approval from an authority not operating under FDA evidence and manufacturing standards is not an adequate demonstration of safety and effectiveness. Anything dispensed here is a compounded medication prepared by a licensed U.S. compounding pharmacy, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

One recent development, stated neutrally: at its July 2026 meeting, the FDA's Pharmacy Compounding Advisory Committee voted 8-5-1 to recommend Semax for the 503A bulk drug substances list, against FDA staff's own recommendation. The vote is advisory, rulemaking has not happened, and the compound's legal status did not change as a result. A licensed provider may still prescribe — that decision is between you and your doctor.

Choosing between semax and selank — or both

Start from the question you want answered, not from the molecule. If the concern is mental clarity, focus, or recovery from a neurological event, Semax's literature was built around those questions. If it is anxiety, stress load, or tension that shows up physically, Selank's was. If both describe you, that is a conversation for a clinician rather than a decision to make from a comparison table.

Bring specifics: what you are noticing, when it started, what else you take, and any history of anxiety disorders, seizure conditions or diabetes — Semax's review data flags blood glucose in people who have it. A provider weighs those against the real state of the evidence: thin, mostly Russian, mostly rodent, mostly intranasal.

Promise is a prescription service: a licensed provider reviews every request, not everyone qualifies, and the provider may decline. You can see where these two sit in the wider catalog on the brain health and memory page.